Purple Biotech Stock Today

PPBT Stock  USD 2.80  0.07  2.56%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
Purple Biotech is selling for under 2.80 as of the 18th of March 2025; that is 2.56 percent increase since the beginning of the trading day. The stock's last reported lowest price was 2.7. Purple Biotech has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
20th of November 2015
Category
Healthcare
Classification
Health Care
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. The company has 2.65 M outstanding shares of which 53.98 K shares are at this time shorted by private and institutional investors with about 2.34 trading days to cover. More on Purple Biotech

Moving together with Purple Stock

  0.83ME 23Andme HoldingPairCorr
  0.78VANI Vivani Medical Earnings Call This WeekPairCorr

Moving against Purple Stock

  0.76VALN Valneva SE ADR Earnings Call TodayPairCorr
  0.61VIGL Vigil NeurosciencePairCorr
  0.6DVAX Dynavax TechnologiesPairCorr
  0.57DMAC DiaMedica TherapeuticsPairCorr
  0.32VERV Verve TherapeuticsPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Purple Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00480.0051
Notably Down
Very volatile
Total Current Liabilities3.8 MM
Notably Down
Slightly volatile
Non Current Liabilities Total133 K140 K
Notably Down
Slightly volatile
Total Assets33.1 M37 M
Moderately Down
Slightly volatile
Total Current Assets8.5 M8.9 M
Notably Down
Slightly volatile
Debt Levels
Purple Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Purple Biotech's financial leverage. It provides some insight into what part of Purple Biotech's total assets is financed by creditors.
Liquidity
Purple Biotech currently holds 4.13 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Purple Biotech has a current ratio of 6.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Purple Biotech's use of debt, we should always consider it together with its cash and equity.

Total Cash From Financing Activities

10.91 Million
Purple Biotech (PPBT) is traded on NASDAQ Exchange in USA. It is located in 4 Oppenheimer Street, Rehovot, Israel, 7670104 and employs 6 people. Purple Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.22 M. Purple Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.65 M outstanding shares of which 53.98 K shares are at this time shorted by private and institutional investors with about 2.34 trading days to cover. Purple Biotech currently holds about 36.02 M in cash with (14.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.0.
Check Purple Biotech Probability Of Bankruptcy
Ownership Allocation
Roughly 94.99 pct. of Purple Biotech outstanding shares are held by general public with 1.98 % owned by insiders and only 3.03 (%) by third-party entities.
Check Purple Ownership Details

Purple Stock Institutional Holders

InstituionRecorded OnShares
Global Retirement Partners, Llc.2024-12-31
16.0
Sound Income Strategies2024-09-30
0.0
Venture Visionary Partners Llc2024-09-30
0.0
Citadel Advisors Llc2024-09-30
0.0
North Star Investment Management Corp2024-09-30
0.0
Wealth Advisors Of Iowa, Llc2024-09-30
0.0
Geode Capital Management, Llc2024-09-30
0.0
Raymond James & Associates2024-09-30
0.0
Jpmorgan Chase & Co2024-12-31
0.0
Kingswood Wealth Advisors Llc2024-12-31
33.6 K
Two Sigma Securities, Llc2024-12-31
15.4 K
View Purple Biotech Diagnostics

Purple Biotech Historical Income Statement

At this time, Purple Biotech's Depreciation And Amortization is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 4.5 M in 2025, despite the fact that EBIT is likely to grow to (19.2 M). View More Fundamentals

Purple Stock Against Markets

Purple Biotech Corporate Management

MA CPAChief OfficerProfile
Fabien SebilleChief OfficerProfile
Michael SchicklerHead AffairsProfile
LLM BScVice OperationsProfile
Ido MorpurgoVP OperationsProfile
Nir LivnehVP AffairsProfile

Additional Tools for Purple Stock Analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.